Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faecal microbiota transplant for persistent critical illness
ACTRN12624000034538Phase 2Not yet recruiting
- Sponsor
- South Metropolitan Health Service
- Start
- Feb 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota in Persistent Critical Illness (PCI) and Gastrointestinal microbiome disorder (GMD), sponsored by South Metropolitan Health Service. Primary endpoint: Safety of nasogastric FMT in ICU patients with persistent critical illness. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Persistent Critical Illness (PCI)Gastrointestinal microbiome disorder (GMD)
Beyond the preview
Go deeper on ACTRN12624000034538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000034538.